In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2014-12-617548 | DOI Listing |
Publication Analysis
Top Keywords
targeting bcr-abl
8
bcr-abl jak2
4
jak2 ph+
4
ph+ issue
4
issue blood
4
blood appelmann
4
appelmann provide
4
provide evidence
4
evidence prolonged
4
prolonged survival
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!